OKYO Pharma Ltd 6-K, filed Sep 7, 2022
OKYO Pharma Ltd (OKYO)
About this 6-K
OKYO Pharma Ltd filed this 6-K on September 7, 2022.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
September 2022
Commission File Number: 001-41386
OKYO Pharma LTD
(Exact Name of Registrant as Specified in Its Charter)
9th Floor
107 Cheapside
London
EC2V 6DN
(Address of registrant’s principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
On September 7, 2022, OKYO Pharma LTD (the “Company”) issued a news service announcement in the United Kingdom announcing the Result of the Annual General Meeting.
The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| OKYO Pharma LTD | ||
| Date: September 7, 2022 | By: | /s/ Gary Jacob |
| Name: | Gary Jacob | |
| Title: | Chief Executive Officer | |
| 3 |
EXHIBIT INDEX
| Exhibit No. |
Description | |
| 99.1 | News Service Announcement, dated September 7, 2022 |
Exhibit 99.1
7 September 2022
OKYO Pharma Limited
(“OKYO” or “Company”)
Result of Annual General Meeting
The board of directors of OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), a bio-pharmaceutical company focused on developing an innovative approach to dry eye care and ocular pain, is pleased to announce that at the Annual General Meeting (“AGM”) of the Company held earlier today all resolutions were duly passed.
The result of the poll, including the proxy voting, is as follows:
| For | Against | Discretion | Withheld | For + Discretion | ||||||||||||||||||||||||||||||||||||||
| Resolution | Description | Votes | % Votes Cast | Votes | % Votes Cast | Votes | % Votes Cast | Votes | Total Votes Cast (excl. Votes Withheld) | Votes | % Votes Cast | |||||||||||||||||||||||||||||||
| RES:001 | REPORT AND ACCOUNTS | 560,824,152 | 99.99852 | % | 325 | 0.00006 | % | 8,000 | 0.00143 | % | 3,000 | 560,832,477 | 560,832,152 | 99.99994 | % | |||||||||||||||||||||||||||
| RES:002 | REMUNERATION REPORT | 560,789,302 | 99.99252 | % | 33,975 | 0.00606 | % | 8,000 | 0.00143 | % | 4,200 | 560,831,277 | 560,797,302 | 99.99394 | % | |||||||||||||||||||||||||||
| RES:003 | RE-ELECT MR W SIMON | 560,823,652 | 99.99843 | % | 825 | 0.00015 | % | 8,000 | 0.00143 | % | 3,000 | 560,832,477 | 560,831,652 | 99.99985 | % | |||||||||||||||||||||||||||
| RES:004 | RE-ELECT DR.G S. JACOB | 560,823,652 | 99.99843 | % | 825 | 0.00015 | % | 8,000 | 0.00143 | % | 3,000 | 560,832,477 | 560,831,652 | 99.99985 | % | |||||||||||||||||||||||||||
| RES:005 | RE-ELECT MR J BRANCACCIO | 560,823,652 | 99.99843 | % | 825 | 0.00015 | % | 8,000 | 0.00143 | % | 3,000 | 560,832,477 | 560,831,652 | 99.99985 | % | |||||||||||||||||||||||||||
| RES:006 | RE-ELECT MR G CERRONE | 560,812,452 | 99.99643 | % | 12,025 | 0.00214 | % | 8,000 | 0.00143 | % | 3,000 | 560,832,477 | 560,820,452 | 99.99786 | % | |||||||||||||||||||||||||||
| RES:007 | RE-ELECT MR.B DENOYER | 560,812,952 | 99.99673 | % | 10,325 | 0.00184 | % | 8,000 | 0.00143 | % | 4,200 | 560,831,277 | 560,820,952 | 99.99816 | % | |||||||||||||||||||||||||||
| RES:008 | APPOINTMENT OF AUDITORS | 560,823,652 | 99.99843 | % | 825 | 0.00015 | % | 8,000 | 0.00143 | % | 3,000 | 560,832,477 | 560,831,652 | 99.99985 | % | |||||||||||||||||||||||||||
| RES:009 | DIRECTORS TO ALLOT SHARES | 560,822,952 | 99.99852 | % | 325 | 0.00006 | % | 8,000 | 0.00143 | % | 4,200 | 560,831,277 | 560,830,952 | 99.99994 | % | |||||||||||||||||||||||||||
| RES:010 | PRE-EMPTION RIGHTS | 560,789,802 | 99.99260 | % | 33,475 | 0.00597 | % | 8,000 | 0.00143 | % | 4,200 | 560,831,277 | 560,797,802 | 99.99403 | % | |||||||||||||||||||||||||||
Further information on votes:
As at 17 August 2022, there were 1,415,040,468 ordinary shares in issue. Shareholders are entitled to one vote per ordinary share. Any vote withheld is not a vote in law and so has not been included in the calculation of the proportion of votes for and against any Resolution.
The resolutions were all passed on a poll, with votes cast in accordance with proxy voting instructions submitted to the Company by the relevant deadline, together with those cast at the AGM itself, and will be available on the National Storage Mechanism, https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
The result of poll and proxy voting will also be available on the Company’s website, www.okyopharma.com.
| Enquiries: | ||
| OKYO Pharma Limited | Gary S. Jacob, Chief Executive Officer
Gabriele Cerrone, Non-Executive Chairman |
Tel: +44 (0)20 7495 2379 |
Optiva Securities Limited (Broker)
|
Robert Emmet |
Tel: +44 (0)20 3981 4173 |